With three newly acquired sites, the company contends it is well positioned to support customers from early phase development to commercial manufacturing.
The drugmaker will add flexible capacity for prefilled syringes and autoinjectors at its Hillsboro site and is expected to begin commercial operations in 2031.
The acquisition increases Piramal’s ownership of the Hyderabad CDMO to 74% and expands its capabilities in vaccines, biologics, and large-molecule manufacturing.
